Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma

Although major progress has been made in the standard treatment for glioblastomas, encompassing the maximal surgical resection, chemotherapy and radiation therapy, it is possible to increase survival rates significantly only in a few patients. Therefore, it is necessary to explore new therapeutic modalities, one of which is immunotherapy.

The aim of the study was to evaluate the efficacy of the combined use of autologous and pooled tumor lysates in comprehensive treatment of patients with glioblastoma.

Materials and Methods. All patients (n=58, including 30 males and 28 females aged 18–70 years) were randomized into three groups, two of which received immunotherapy based on injection of autologous dendritic cells pulsed with autologous tumor lysates (first protocol) or pooled lysates (second protocol) from more than one tumor, in addition to the planned standard treatment. The patients of group 3 (control) received the standard comprehensive treatment encompassing the maximum safe tumor resection followed by radiation therapy and chemotherapy.

Results. The tolerability of both applied immunotherapy protocols was good: there were no anaphylactic reactions observed or patients who prematurely discontinued participation in the study. The final analysis of the data revealed no significant differences in median survival values of patients in each of the three groups. However, when analyzing the Karnofsky Performance Status in patients of group 2, it was found that it tended to improve.

Conclusion. The study shows that the proposed immunotherapy protocols are safe for clinical use and have the potential to improve the patient’s life quality. However, these findings should be considered intermediate until the findings of multicenter randomized clinical trials with a larger number of patients are obtained.

1. Glioblastoma. De Vleeschouwer S. (editor). Brisbane (AU): Codon Publications; 2017, https://doi.org/10.15586/codon.glioblastoma.2017.fr.
2. Batash R., Asna N., Schaffer P., Francis N., Schaffer M. Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem 2017; 24(27): 3002–3009, https://doi.org/10.2174/0929867324666170516123206.
3. Wirsching H.G., Galanis E., Weller M. Glioblastoma. Handb Clin Neurol 2016; 134: 381–397, https://doi.org/10.1016/b978-0-12-802997-8.00023-2.
4. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131(6): 803–820, https://doi.org/10.1007/s00401-016-1545-1.
5. Hanif F., Muzaffar K., Perveen K., Malhi S.M., Simjee S.U. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017; 18(1): 3–9.
6. Dyachenko A.A., Subbotina A.V., Izmailov T.R., Krasilnikov A.V., Valkov M.Y. Epidemiology of primary brain tumors: (overview). Vestnik RNTsRR MZ RF 2013; 13: 1–37.
7. Touat M., Idbaih A., Sanson A., Ligon K.L. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 2017; 28(7): 1457–1472, https://doi.org/10.1093/annonc/mdx106.
8. Delgado-López P.D., Corrales-García E.M. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 2016; 18(11): 1062–1071, https://doi.org/10.1007/s12094-016-1497-x.
9. Harder B.G., Blomquist M.R., Wang J., Kim A.J., Woodworth G.F., Winkles J.A., Loftus J.C., Tran N.L. Developments in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma. Front Oncol 2018; 8: 462, https://doi.org/10.3389/fonc.2018.00462.
10. Huang B., Zhang H., Gu L., Ye B., Jian Z., Stary C., Xiong X. Advances in immunotherapy for glioblastoma multiforme. J Immunol Res 2017; 3597613: 1–11, https://doi.org/10.1155/2017/3597613.
11. Vakilian A., Khorramdelazad H., Heidari P., Rezaei Z.S., Hassanshahi G. CCL2/CCR2 signaling pathway in glioblastomamultiforme. Neurochem Int 2017; 103: 1–7, https://doi.org/10.1016/j.neuint.2016.12.013.
12. Tanaka A., Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res 2017; 27(1): 109–118, https://doi.org/10.1038/cr.2016.151.
13. Arenas-Ramirez N., Zou C., Popp S., Zingg D., Brannetti B., Wirth E., Calzascia T., Kovarik J., Sommer L., Zenke G., Woytschak J., Regnier C.H., Katopodis A., Boyman O. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med 2016; 8(367): 367ra166, https://doi.org/10.1126/scitranslmed.aag3187.
14. Walker L.S.K. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 2013; 45: 49–57, https://doi.org/10.1016/j.jaut.2013.06.006.
15. Chang A.L., Miska J., Wainwright D.A., Dey M., Rivetta C.V., Yu D., Kanojia D., Pituch K.C., Qiao J., Pytel P., Han Y., Wu M., Zhang L., Horbinski C.M., Ahmed A.U., Lesniak M.S. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory t cells and myeloid-derived suppressor cells. Cancer Res 2016; 76(19): 5671–5682, https://doi.org/10.1158/0008-5472.can-16-0144.
16. Ooi Y.C., Tran P., Ung N., Thill K., Trang A., Fong B.M., Nagasawa D.T., Lim M., Yang I. The role of regulatory T-cells in glioma immunology. Clin Neurol Neurosurg 2014; 119: 125–132, http://doi.org/10.1016/j.clineuro.2013.12.004.
17. Prins R.M., Soto H., Konkankit V., Odesa S.K., Eskin A., Yong W.H., Nelson S.F., Liau L.M. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17(6): 1603–1615, https://doi.org/10.1158/1078-0432.ccr-10-2563.
18. Dutoit V., Migliorini D., Walker P.R., Dietrich P.Y. Immunotherapy of brain tumors. Prog Tumor Res 2015; 42: 11–21, https://doi.org/10.1159/000436986.
19. Vandenberk L., Van Gool S.W. Treg infiltration in glioma: a hurdle for antiglioma immunotherapy. Immunotherapy 2012; 4(7): 675–678, https://doi.org/10.2217/imt.12.64.
20. Sullivan J.P., Nahed B.V., Madden M.W., Oliveira S.M., Springer S., Bhere D., Chi A.S., Wakimoto H., Rothenberg S.M., Sequist L.V., Kapur R., Shah K., Iafrate A.J., Curry W.T., Loeffler J.S., Batchelor T.T., Louis D.N., Toner M., Maheswaran S., Haber D.A. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 2014; 4(11): 1299–1309, https://doi.org/10.1158/2159-8290.cd-14-0471.
21. Jimsheleishvili S., Alshareef A.T., Papadimitriou K., Bregy A., Shah A.H., Graham R.M., Ferraro N., Komotar R.J. Extracranial glioblastoma in transplant recipients. J Cancer Res Clin Oncol 2014; 140(5): 801–807, https://doi.org/10.1007/s00432-014-1625-3.
22. Tivnan A., Heilinger T., Lavelle E.C., Prehn J.H.M. Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol 2017; 131(1): 1–9, https://doi.org/10.1007/s11060-016-2299-2.
23. Tyrinova T.V., Leplina O.Y., Tikhonova M.A., Shevela E.Y., Ostanin A.A., Chernykh E.R., Mishinov S.V., Stupak V.V., Pendyurin I.V., Shilov A.G., Alyamkina E.A., Rubtsova N.V., Bogachev S.S., Ostanin A.A., Chernykh E.R. Сytotoxic activity of ex-vivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients. Cell Immunol 2013; 284(1–2): 146–153, https://doi.org/10.1016/j.cellimm.2013.07.013.
24. Pendyurin I.V., Stupak V.V., Mishinov S.V., Ostanin A.A., Chernykh E.R. Kombinirovannaya immunoterapiya i immunologicheskie prediktory vyzhivaniya v lechenii bol’nykh so zlokachestvennymi gliomami. V kn.: Sibirskiy mezhdunarodnyy neyrokhirurgicheskiy forum. Sbornik nauchnykh materialov [Combined immunotherapy and immunological predictors of survival in the treatment of patients with malignant gliomas. In: Siberian International Neurosurgical Forum. Collection of scientific materials]. Novosibirsk; 2012; p. 210.
25. Fadul C.E., Fisher J.L., Hampton T.H., Lallana E.C., Li Z., Gui J., Szczepiorkowski Z.M., Tosteson T.D., Rhodes C.H., Wishart H.A., Lewis L.D., Ernstoff M.S. Immune response in patients with newly diagnosed glioblastomamultiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011; 34(4): 382–389, https://doi.org/10.1097/cji.0b013e318215e300.
26. Lim M., Xia Y., Bettegowda C., Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018; 15(7): 422, https://doi.org/10.1038/s41571-018-0003-5.
27. Wilcox J.A., Ramakrishna R., Magge R. Immunotherapy in glioblastoma. World Neurosurg 2018; 116: 518–528, https://doi.org/10.1016/j.wneu.2018.04.020.
28. Mishinov S.V., Stupak V.V., Tyrinova T.V., Leplina O.Y., Ostanin A.A., Chernykh E.R. Immunotherapeutic protocols in adjuvant treatment of supratentorial high grade gliomas (literature review and results of own research). Sovremennye problemy nauki i obrazovaniya 2018; 6: 50.
29. Chernykh E.R., Leplina O.Yu., Ostanin A.A., Nikonov S.D., Stupak V.V., Kozlov Yu.P. Method for immunotherapy of cerebral malignant tumors. Patent RU 2262941.2005.

Mishinov S.V., Budnik A.Ya., Stupak V.V., Leplina O.Yu., Tyrinova T.V., Ostanin A.A., Chernykh E.R. Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma. Sovremennye tehnologii v medicine 2020; 12(2): 34, https://doi.org/10.17691/stm2020.12.2.04